Literature DB >> 31199468

Response to Habel and Buist.

Marc D Ryser1,2, E Shelley Hwang3.   

Abstract

Mesh：

Year:  2020        PMID： 31199468      PMCID： PMC7019085          DOI： 10.1093/jnci/djz120

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN： 0027-8874            Impact factor:   13.506


× No keyword cloud information.
  4 in total

1.  Long-term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B-17 and B-24 randomized clinical trials for DCIS.

Authors:  Irene L Wapnir; James J Dignam; Bernard Fisher; Eleftherios P Mamounas; Stewart J Anderson; Thomas B Julian; Stephanie R Land; Richard G Margolese; Sandra M Swain; Joseph P Costantino; Norman Wolmark
Journal:  J Natl Cancer Inst       Date:  2011-03-11       Impact factor: 13.506

2.  Impact of Age on Risk of Recurrence of Ductal Carcinoma In Situ: Outcomes of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.

Authors:  Patricia A Cronin; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2016-05-19       Impact factor: 5.344

3.  Decreasing Recurrence Rates for Ductal Carcinoma In Situ: Analysis of 2996 Women Treated with Breast-Conserving Surgery Over 30 Years.

Authors:  Preeti Subhedar; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee
Journal:  Ann Surg Oncol       Date:  2015-07-28       Impact factor: 5.344

4.  The COMET (Comparison of Operative versus Monitoring and Endocrine Therapy) trial: a phase III randomised controlled clinical trial for low-risk ductal carcinoma in situ (DCIS).

Authors:  E Shelley Hwang; Terry Hyslop; Thomas Lynch; Elizabeth Frank; Donna Pinto; Desiree Basila; Deborah Collyar; Antonia Bennett; Celia Kaplan; Shoshana Rosenberg; Alastair Thompson; Anna Weiss; Ann Partridge
Journal:  BMJ Open       Date:  2019-03-12       Impact factor: 2.692
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.